

## **Pre-Congress Symposium 8**

Oncology & Theranostics Committee / European Association of Urology - EAU

**Saturday, October 12, 13:00-16:00**

### **Session Title**

**PSMA Theranostics and Beyond**

### **Chairpersons**

Jochen Walz (Marseille, France / EAU)

Johannes Czernin (Los Angeles, United States of America)

### **Programme**

13:00 - 13:20 Jochen Walz (Marseille, France / EAU): Defining the Landscape of Potential Candidates for PSMA-RLT

13:20 - 13:40 Bernd Krause (Rostock, Germany): Overview of Clinical Data for 177Lu-PSMA

13:40 - 14:00 Matthias Eiber (Munich, Germany): PSMA RLT beyond 177Lu-PSMA

14:00 - 14:15 Discussion

### **14:15 - 14:45 Coffee Break**

14:45 - 15:10 Johannes Czernin (Los Angeles, United States of America): Overcoming Resistance to PSMA RLT

15:10 - 15:25 John Babich (New York, United States of America): Targets Beyond PSMA

15:25 - 16:00 Discussion

### **Educational Objectives**

1. Understand the current therapeutic landscape for metastatic prostate cancer patients
2. Learn about the currently available clinical data of PSMA-directed radioligand therapy
3. Realize the limitations of PSMA-targeted radioligand therapy and learn about approaches to overcome resistance

### **Summary**

PSMA-directed theranostics is one of the most exciting and rapidly developing fields in nuclear medicine. The aim of this joint EAU/EANM session is to teach the audience the current therapeutic landscape for patients with metastatic prostate cancer, to give an update of the currently available clinical data for 177Lu-PSMA 617 radioligand therapy, and to discuss alternative radionuclides for PSMA-directed treatment. After the break this session dares to look into the future by elaborating options to overcome resistance to radioligand therapy and by discussing potential new targets beyond PSMA for prostate cancer.

### **Key Words**

Prostate Cancer, PSMA, Radioligand Therapy